A correlation between diminished expression of TβRII in breast cancer cells and enhanced in vivo malignant behaviour has been observed in studies based on patient specimens and an established cell line (Gobbi et al, 2000), suggesting that attenuation of the growth inhibitory TGF-β autocrine loop in breast cancers worsens clinical outcome. This evidence concerns the gene TGFB1 and breast cancer.